Advice
following an abbreviated submission:
somatrogon (Ngenla®) is accepted for use within NHSScotland.
Indication under review: for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
Somatrogon offers an additional treatment choice in the therapeutic class of recombinant human growth hormones for this indication.
Download detailed advice721KB (PDF)
Medicine details
- Medicine name:
- somatrogon (Ngenla)
- SMC ID:
- SMC2493
- Indication:
For treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 August 2022